Celcuity Inc CELC
News
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Celcuity Appoints David Gryska To Its Board Of Directors
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Correction to Celcuity Gets FDA Approval Headline
Celcuity Gets FDA Approval for Breast Cancer Drug
Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results

